Oncologic Outcomes in Patients Undergoing Radical Cystectomy for non–muscle-invasive bladder cancer (NMIBC) Following BCG Therapy Failure. Dr. Oberneder highlighted that the U.S. FDA has approved ...

Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral ...

The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ.

The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

PRINCETON, NJ, USA I April 26, 2025 I UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions ...

Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical ...

Intravesical therapy is central to managing non-muscle-invasive bladder cancer (NMIBC); yet, recurrence and progression remain common, underscoring the need for new treatments. This systematic review ...

compared to intravesical chemotherapy, either mitomycin C, or gemcitabine, using an induction course of 4 to 6 weekly induction, followed by a 6 to 12 monthly maintenance therapy. The primary end ...

As a therapist, I've seen firsthand how powerful a tool therapy can be for improving mental health and building mental strength. But it’s certainly not the only tool, and therapy isn’t for ...

The celebrity was sitting at a Mexican restaurant in Orlando last month when a group of women walking by glanced at him and whispered. One of them worked up the courage to ask: “Is that Alex The ...